Experts interviewed for a feature published by Women's Health say synthetic injectable peptides marketed for fitness, recovery and sleep are not supported by solid research, with the exception of GLP-1 drugs. The category, in their telling, has grown far faster than the evidence behind it.

Peptides are "short chains of proteins" naturally made by the body, according to Katrin Svensson, PhD, an associate professor in the Department of Pathology at Stanford University who studies them. The gut releases hormones including glucagon-like peptide 1 after eating to signal fullness to the brain, she says, and the peptides your body makes are not the same thing as the injectable synthetic versions, which the article notes are not yet FDA-approved.

What people are injecting

On the weight-loss side the names are familiar: tirzepatide and semaglutide, both GLP-1s, along with retatrutide, per Elena Christofides, MD, a double-board certified endocrinology and internal medicine physician in Columbus, Ohio. A 2024 review in Cureus is cited linking GLP-1s to benefits for cardiovascular and renal health, obstructive sleep apnea, and neurodegenerative diseases.

For fitness, Christofides points to the compounds ending in "morelin," such as sermorelin, tesamorelin and ipamorelin, which trigger growth hormone release. A 2026 review in a Journal of the American Academy of Orthopaedic Surgeons publication is cited as associating them with fracture healing and joint preservation.

Where the recovery evidence stops

BPC-157 is the recovery compound of the moment, and the human data behind it is one small 2021 study in Alternative Therapies in Health and Medicine: 11 of 12 patients given a BPC-157 shot for knee pain had significant improvement, and three of four given BPC-157 plus TB4 did. That study was small and poorly constructed, with unclear timing and frequency of dosing, which is a lot of enthusiasm resting on very little.

Sleep peptides such as pinealon have only "small science" behind them, Christofides says, meaning scattered small trials and animal testing. "The evidence is very low and there's nothing that is supporting that they're actually doing anything," says Svensson.

A legal gray zone

Christofides says synthetic peptides sit "legally in a gray zone," and that compounded versions sold by online sellers, some in China, are not something she can recommend in good faith. Meanwhile the FDA's Pharmacy Compounding Advisory Committee recently voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to a list pharmacies may compound.

Bottom line

Oncologist Ezekiel Emanuel, MD, PhD, of the University of Pennsylvania calls the trend "totally insane," saying people do not have to spend $500 every few weeks on peptide infusions to be healthy. The experts quoted say anyone interested should talk with a healthcare provider first, and that outside GLP-1s the evidence remains unsettled.